Citations

Showing 10 of 108152 citations.

Exceptional Responders in Oncology
Cummings, Mackenzie , Lehrer, Eric J. , Drabick, Joseph J. , Gusani, Niraj J. , Trifiletti, Daniel M. , Zaorsky, Nicholas G.

Mayo Clinic

American Journal of Clinical Oncology | July 17, 2019 | Volume: 42 | Issue: 8 | Pages: 624-635

10.1097/coc.0000000000000572 | PMID 31313679 Get It

Purpose: We aim to systematically review and analyze the available literature on “exceptional responders” in oncology. We hypothesize that survival or patients with an exceptional response may be predicted based on clinical factors. Materials and Methods: A PICOS/PRISMA/MOOSE selection protocol was used to find studies that reported oncology patients with an exceptional response. A total of 333 initial articles were screened, and 76 articles were included, accounting for 85 patients. The primary outcome was survival after exceptional response therapy (ERT). The secondary outcome was survival since diagnosis. Univariate and multivariate analyses were conducted for both outcomes with 17 covariates. Results: The median age was 52 years (interquartile range, 35-66 y), 51.8% were male individuals, 18 (21.2%) had lung cancer, and 1 patient (1%) met all National Cancer Institute criteria for exceptional response. The most common treatment resulting in exceptional response was a form of chemotherapy (49.2%) followed by targeted therapy (26.8%) and radiation therapy (7.7%). The median time from diagnosis to initiation of ERT was 7.92 months (interquartile range, 0-24.72 mo). On multivariate analysis of survival after initiation of ERT, there were no predictors of exceptional response. On multivariate analysis of survival since diagnosis, predictors of prolonged survival included time between diagnosis and ERT initiation (hazard ratio, 0.52; 95% confidence interval, 0.32-0.87; P=0.0124) and single prior surgery versus none (0.08; 95% confidence interval, 0.01-0.98; P=0.04853). Conclusions: There were no clinically apparent patient or treatment factors that predicted favorable survival following ERT; instead, reporting of exceptional response appears to be biased.
Reply to Annis et al.: Is quasi-Mendelian mtDNA competition enough to drive transmission of paternal mtDNA?
Slone, Jesse , Luo, Shiyu , Atwal, Paldeep S , Huang, Taosheng

Mayo Clinic

Proceedings of the National Academy of Sciences | July 16, 2019 | Volume: 116 | Issue: 30 | Pages: 14799-14800

10.1073/pnas.1909445116 | PMID 31311873 Get It

Response to Rosenblatt et al.
Okafor, Philip N. , Nnadi, Augustine K., Okoli, Okwuchukwu, Nwaiwu, Obioma, Huang, Alice E.

Mayo Clinic

American Journal of Gastroenterology | July 16, 2019 | Volume: 114 | Issue: 8 | Pages: 1357-1358

10.14309/ajg.0000000000000322 | PMID 31318707 Get It

Technical Note: Assessment of scatter originating from the x‐ray tube collimator assembly of modern angiography systems
Tao, Ashley , Miller, Daniel L. , Hindal, Mark D. , Fetterly, Kenneth A. , Tao, Ashley T , Miller, Daniel , Hindal, Mark

Mayo Clinic

Medical Physics | July 16, 2019 | Volume: 46 | Issue: 10 | Pages: 4371-4380

10.1002/mp.13720 | PMID 31310325 Get It

PurposeWhile scatter from the patient is assumed to be the primary source of occupational radiation dose associated with fluoroscopically guided interventional procedures, the potential contribution of scatter from the x‐ray collimator assembly is unknown. The purpose of this work was to survey clinical x‐ray angiography systems to assess the potential contribution of collimator assembly scatter on occupational radiation dose.MethodsExperimental methods were designed to measure the relative contributions of scatter originating from within the collimator assembly of the x‐ray tube to total scatter, which included scatter from a patient‐simulating phantom. Measurements were acquired as a function of lateral distance from the x‐ray beam center using a posterior anterior (PA) projection and at a fixed location for variable right anterior oblique to left anterior oblique projections in the range −90º to 90º. For one system, the collimator assembly was partially disassembled to assess the scatter contribution of individual components. For two systems, 0.5 mm Pb was added to the inner surface of the collimator assembly cover and tested for efficacy to block collimator assembly scatter.ResultsConsidering all x‐ray systems and only the PA projection, collimator assembly scatter contributed 20–50% to total scatter. For x‐ray projection angles of −90º to 90º, the relative contribution of collimator assembly to total scatter was dependent on projection angle and ranged from 5% to 56%. X‐ray systems with kerma‐area product meters demonstrated higher collimator assembly scatter than those without. Considering all projection angles, the addition of 0.5 mm Pb to the inside of the collimator assembly cover reduced collimator assembly scatter from 28% to 16% of total scatter for both systems.ConclusionFindings from this work suggest that contemporary radiation safety practices and guidelines should be revised to account for scatter originating from the collimator assembly of angiographic x‐ray tubes.
Outcome of combined cryo‐ and radiofrequency‐catheter ablation in patients with supraventricular tachycardias
Miyamoto, Koji , Mulpuru, Siva K. , Deshmukh, Abhishek , Asirvatham, Samuel J. , Munger, Thomas M. , Friedman, Paul A. , Packer, Douglas L. , Kapa, Suraj , Mulpuru, Siva K , Asirvatham, Samuel J , Friedman, Paul A , Kapa, Suraj

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 16, 2019 | Volume: 30 | Issue: 10 | Pages: 1960-1966

10.1111/jce.14068 | PMID 31310387 Get It

AbstractBackgroundThere are few data regarding the outcome of a combined cryo‐ and radiofrequency (RF)‐catheter ablation of various types of supraventricular tachycardias (SVTs) originating from near the normal conduction system.METHODSWe analyzed all patients undergoing combined cryo‐ and RF‐ catheter ablation at Mayo Clinic, Rochester, MN as part of the ablation of SVTs with potential risks of injury to the normal conduction system. This study aimed to assess the outcome of a combined cryo‐ and RF‐catheter ablation of various types of SVTs.RESULTSThe study population consisted of 54 patients (38 ± 17 years, 32 men). A combined cryo‐ and RF‐catheter ablation was attempted for septal accessary pathways (APs) in 26, atrioventricular nodal reentrant tachycardia (AVNRT) in 14, atrial tachycardia (AT) in 7, and junctional ectopic tachycardia in 7 patients. Forty‐one patients (76%) were successfully ablated with cryoablation, and RF ablation after an unsuccessful cryoablation ablated the SVTs successfully at the same location in 6 patients (11%). Complication occurred in 1 patient (deep vein thrombosis). The cumulative freedom from SVT rate at 30 days after the procedure was 78% and there was no significant difference in the recurrence rate among the SVTs.CONCLUSIONA combined cryo‐ and RF‐catheter ablation is clinically effective in patients undergoing SVT ablation with the potential risk of injury to the normal conduction system.
Editorial
Stokken, Janalee K.

Mayo Clinic

American Journal of Rhinology & Allergy | July 16, 2019 | Volume: 33 | Issue: 4 | Pages: 345-346

10.1177/1945892419862657 | PMID 31309842 Get It

Diabetes Is Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Cirrhosis From Nonalcoholic Fatty Liver Disease
Yang, Ju Dong , Ahmed, Fowsiyo , Mara, Kristin C. , Addissie, Benyam D., Allen, Alina M. , Roberts, Lewis R. , Roberts, Lewis R , Mara, Kristin C , Allen, Alina M , Yang, Ju Dong , Gores, Gregory J.

Mayo Clinic

Hepatology | July 16, 2019 | Volume: 71 | Issue: 3 | Pages: 907-916

10.1002/hep.30858 | PMID 31309602 Get It

Diabetes increases the risk of liver disease progression and cirrhosis development in patients with nonalcoholic steatohepatitis (NASH). The association between diabetes and the risk of hepatocellular carcinoma (HCC) in NASH patients with cirrhosis is not well quantified. All patients with the diagnosis of NASH cirrhosis seen at Mayo Clinic Rochester between January 2006 and December 2015 were identified. All adult liver transplant registrants with NASH between 2004 and 2017 were identified using the United Network for Organ Sharing (UNOS)/Organ Procurement and Transplantation registry for external validation. Cox proportional hazard analysis was performed to investigate the association between diabetes and HCC risk. Among 354 Mayo Clinic patients with NASH cirrhosis, 253 (71%) had diabetes and 145 (41%) were male. Mean age at cirrhosis evaluation was 62. During a median follow‐up of 47 months, 30 patients developed HCC. Diabetes was associated with an increased risk of developing HCC in univariate (hazard ratio [HR] = 3.6; 95% confidence interval [CI] = 1.1‐11.9; P = 0.04) and multivariable analysis (HR = 4.2; 95% CI = 1.2‐14.2; P = 0.02). In addition, age (per decade, HR = 1.8; 95% CI = 1.2‐2.6; P < 0.01) and low serum albumin (HR = 2.1; 95% CI = 1.5‐2.9; P < 0.01) were significantly associated with an increased risk of developing HCC in multivariable analysis. Other metabolic risk factors, including body mass index, hyperlipidemia, and hypertension, were not associated with HCC risk. Among UNOS NASH registrants (N = 6,630), 58% had diabetes. Diabetes was associated with an increased risk of developing HCC in univariate (HR = 1.4; 95% CI = 1.1‐1.8; P < 0.01) and multivariable (HR = 1.3; 95% CI = 1.0‐1.7; P = 0.03) analysis. Conclusion: Diabetes is associated with an increased risk of HCC in patients with NASH cirrhosis.
Effect of Intensive and Standard Clinic‐Based Hypertension Management on the Concordance Between Clinic and Ambulatory Blood Pressure and Blood Pressure Variability in SPRINT
Ghazi, Lama , Bates, Jeffrey T. , Chang, Tara I. , Haley, William E. , Johnson, Karen, Kostis, William J. , Simmons, Debra L., Taylor, Addison A. , Whelton, Paul K. , Wright, Jackson T. , Bhatt, Udayan, Drawz, Paul E. , Johnson, Karen , Drawz, Paul , Pajewski, Nicholas M. , Rifkin, Dena E. , Cushman, William C. , Glasser, Stephen P. , Papademetriou, Vasilios , Rahman, Mahboob , Ghazi, Lama

Mayo Clinic

Journal of the American Heart Association | July 16, 2019 | Volume: 8 | Issue: 14 | Pages: No page available

10.1161/jaha.118.011706 | PMID 31307270 Get It

Background Blood pressure ( BP ) varies over time within individual patients and across different BP measurement techniques. The effect of different BP targets on concordance between BP measurements is unknown. The goals of this analysis are to evaluate concordance between (1) clinic and ambulatory BP , (2) clinic visit‐to‐visit variability and ambulatory BP variability, and (3) first and second ambulatory BP and to evaluate whether different clinic targets affect these relationships. Methods and Results The SPRINT (Systolic Blood Pressure Intervention Trial) ambulatory BP monitoring ancillary study obtained ambulatory BP readings in 897 participants at the 27‐month follow‐up visit and obtained a second reading in 203 participants 293±84 days afterward. There was considerable lack of agreement between clinic and daytime ambulatory systolic BP with wide limits of agreement in Bland‐Altman plots of −21 to 34 mm Hg in the intensive‐treatment group and −26 to 32 mm Hg in the standard‐treatment group. Overall, there was poor agreement between clinic visit‐to‐visit variability and ambulatory BP variability with correlation coefficients for systolic and diastolic BP all <0.16. We observed a high correlation between first and second ambulatory BP ; however, the limits of agreement were wide in both the intensive group (−27 to 21 mm Hg) and the standard group (−23 to 20 mm Hg). Conclusions We found low concordance in BP and BP variability between clinic and ambulatory BP and second ambulatory BP . Results did not differ by treatment arm. These results reinforce the need for multiple BP measurements before clinical decision making.
Review article: biological mechanisms for symptom causation by individual FODMAP subgroups ‐ the case for a more personalised approach to dietary restriction
Wang, Xiao Jing , Camilleri, Michael , Vanner, Stephen , Tuck, Caroline J. , Tuck, Caroline , Wang, Xiao Jing

Mayo Clinic

Alimentary Pharmacology & Therapeutics | July 16, 2019 | Volume: 50 | Issue: 5 | Pages: 517-529

10.1111/apt.15419 | PMID 31309595 Get It

Summary Background Due to the paucity of targeted therapy for irritable bowel syndrome (IBS), many patients turn to dietary modifications for symptom management. The combination of five subgroups of poorly absorbed and rapidly fermented carbohydrates—fructans, galacto‐oligosaccharides, lactose, excess fructose and polyols—are thought to trigger gastrointestinal symptoms and are referred to collectively as “FODMAPs”. Aims To examine the biological plausibility and mechanisms by which foods high in specific FODMAP subgroups cause symptoms, and to use this information to explore the possibility of targeting select dietary components to allow for a more personalised approach to dietary adjustment Methods Recent literature was analysed via search databases including Medline, PubMed and Scopus. Results Lactose, fructans and galacto‐oligosaccharides have strong biologic plausibility for symptom generation due to lack of hydrolases resulting in distention from osmosis and rapid fermentation. However, excess fructose and polyols may only cause symptoms in specific individuals when consumed in high doses, but this remains to be established. There is evidence to suggest that certain patient characteristics such as ethnicity may predict response to lactose, but differentiation of other subgroups is difficult prior to dietary manipulation. Conclusions While some clear mechanisms of action for symptom generation have been established, further research is needed to understand which patients will respond to specific FODMAP subgroup restriction. We suggest that clinicians consider in some patients a tailored, personalised “bottom‐up” approach to the low‐FODMAP diet, such as dietary restriction relevant to the patients’ ethnicity, symptom profile and usual dietary intake.
Clinical Reasoning: A misdiagnosis of atypical trigeminal neuralgia
Duvall, Jaclyn R., Robertson, Carrie E. , Robertson, Carrie E

Mayo Clinic

Neurology | July 16, 2019 | Volume: 93 | Issue: 3 | Pages: 124-131

10.1212/wnl.0000000000007790 | PMID 31308162 Get It